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Abstract
Background:  Photodynamic therapy (PDT) using 5-aminolevulinic acid (5-ALA) is a skin cancer
therapy that still has limitations due to the low penetration of this drug into the skin. We have
proposed in this work a delivery system for 5-ALA based on liposomes having lipid composition
similar to the mammalian stratum corneum (SCLLs) in order to optimize its skin delivery in
Photodynamic Therapy (PDT) of skin cancers.
Methods:  SCLLs were obtained by reverse phase evaporation technique and size distribution of
the vesicles was determinated by photon correlation spectroscopy. In vitro permeation profile was
characterized using hairless mouse skin mounted in modified Franz diffusion cell.
Results:  Size exclusion chromatography on gel filtration confirmed vesicle formation. SCLLs
obtained by presented a degree of encapsulation of 5-ALA around 5.7%. A distribution of vesicle
size centering at around 500 nm and 400 nm respectively for SCLLs and SCLLs containing 5-ALA
was found. In vitro 5-ALA permeation study showed that SCLLs preparations presented higher skin
retention significantly (p < 0.05) on the epidermis without SC + dermis, with a decreasing of skin
permeation compared to aqueous solution.
Conclusions:  The in vitro delivery performance provided by SCLLs lead to consider this systems
adequate for the 5-ALA-PDT of skin cancer, since SCLLs have delivered 5-ALA to the target skin
layers (viable epidermis + dermis) to be treated by topical PDT of skin cancer.
Background
Photodynamic therapy (PDT) is a modality of experi-
mental cancer treatment using a photosensitizer, which
localizes in tumor tissue and can produce tissue destruc-
tion upon absorption of light of an appropriate wave-
length and dose [1]. The topical application of 5-
aminolevulinic acid (5-ALA) followed by light irradiation
is a new concept of PDT [2]. 5-ALA is a prodrug that can
be converted in situ into a highly fluorescent substance,
protoporphyrin IX (PpIX), an effective photosensitizer
Published: 30 August 2001
BMC Dermatology 2001, 1:5
Received: 20 March 2001
Accepted: 30 August 2001
This article is available from: http://www.biomedcentral.com/1471-5945/1/5
© 2001 Pierre et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-com-
mercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact info@biomedcentral.comBMC Dermatology 2001, 1:5 http://www.biomedcentral.com/1471-5945/1/5
by the heme biosynthetic pathway. The presence of exog-
enous 5-ALA bypasses feedback control, and thus may
induce intracellular accumulation of photosensitizing
concentrations of PpIX [3]. Topical photodynamic ther-
apy using 5 aminolevulinic acid (5-ALA-PDT) has shown
to be highly efficient for the topical treatment of a variety
of superficial skin malignances [4]; it presents advantag-
es over conventional treatments, like surgery, elec-
trodessication, cryosurgery, topical application of
podophylin or 5-fluorouracil, and radiotherapy [5]. 5-
ALA is a hydrophilic molecule and does not easily pene-
trate through intact skin or cell membranes. In order to
improve the efficacy of ALA-PDT, particularly in thicker
lesions, a number of options have been investigated.
Penetration enhancers have been used to improve skin
distribution of 5-ALA into the skin [6] and iron chelators
[7] have been added to enhance the production of photo-
sensitizer PpIX. 5-ALA application and light exposure
protocols have been proposed [8]. Iontophoresis [9] and
ultrasound [10] have been studied as physical methods
to increase skin penetration of 5-ALA. In both case, en-
hanced production of PpIX in the skin was observed. 5-
ALA ester derivatives which present more lipophilic
properties have been synthesized, higher PpIX level in
different cell cultures having been found for these com-
pounds compared to 5-ALA itself [11].
Delivery systems that can improve the tissue penetration
and retention of 5-ALA lead to a desirable accumulation
of PpIX in the skin, optimizing the PDT in this way. Lip-
ids present in human stratum corneum (SC) are cera-
mides, cholesterol, free fatty acids and cholesteryl
sulfate; phospholipids are absent [12]. These lipids are
termed "skin lipids" and are arranged in a bilayer sheet
structures filling the intercellular space in the SC. In the
topical administration of drugs, this barrier must be
overcome in order to provide sufficient drug amounts at
the target tissue. The properties of human SC lipids are
of specific interest in this context [13]. One of the first ex-
perimental approaches involved the examination of
model lipid liposomes, the so-called SCLLs made from
commercial lipids. SCLLs have been proposed as a topi-
cal drug carrier system [14] because their lipid composi-
tion is similar to SC lipids, which enables these systems
to penetrate the epidermal barrier to a greater extent and
act as "drug localizers" [15]. The main objective of the
present work is to propose a topical delivery system for
5-ALA, based on SCLLs and to evaluate its in vitro skin
release profile from these preparations.
Materials and methods
Materials
5-ALA-HCl, bovine ceramide (Type III), cholesterol, pal-
mitic acid and colesteryl sulfate were purchased from
Sigma. All other chemicals were analytical or HPLC
grade.
Preparation of SCLLs by the reverse phase evaporation 
technique
Individual lipids were combined to obtain 10 mg of a
mixture containing lipids at the following concentrations
(w/w): ceramide (50%), cholesterol (28%), palmitic acid
(17%) and colesteryl sulfate (5%) in close approximation
of the composition of SC lipids [12]. One mol % α -tocof-
erol was added to this formulations, as an antioxidant.
Large unilamelar liposomes were prepared by reverse
phase evaporation [16]. The lipidic mixture was dis-
solved in a mixture of diethyl ether: chloroform (1:1 vol-
ume ratio) to a volume of 50 mL in appropriate flask, and
sonicated for 20–30 min, The temperature was main-
tained between 5 and 10°C using a ice-bath. After com-
plete dissolution of the lipidic mixture, the aqueous
phase (sodium acetate 100 mM buffer, pH 5.0) contain-
ing 5-ALA to yield a ratio of drug: lipids 1:3 was added.
The resulting two-phase system was sonicated for 20–30
min in a bath-type sonicator and was placed on a rotator
evaporator at 20–25°C to remove the organic solvent un-
der reduced pressure. The preparation was then heated
at 70°C (using a thermo barrel attached to a circulating
water-bath); this temperature is above to gel-liquid crys-
tal transition temperature of the hydrated SC lipids (Tc =
65°C). The preparation containing 5 mg lipid/mL was
then extruded using a stainless steel extrusion device (Li-
pex Biomembranes, Vancouver, BC, Canada) at 70°C
through polycarbonate filters (Nucleopore Corporation,
Pleasaton, Calif, USA) to an initial pore size of 5 µm and
subsequently of 1 µm.
Characterization of SCLLs by size exclusion chromatogra-
phy
SCLLs preparations were subjected to molecular sieve
chromatography on a Sephadex G-75 column (15 mm ×
670 mm) at room temperature, and eluted with a buff-
ered sodium acetate (100 mM, pH 5.0) solution. Fraction
collector, at a flow rate of 0.3 mL/min collected the efflu-
ents. Absorbance measurements at 246 nm were done in
the collected fractions in order to determine the elution
profile of the SCLLs. 5-ALA was assayed in the collected
fractions by the fluorimetric assay [17]. Prior to the 5-
ALA assay, 250 µL ethanol was added to the liposomal
fractions for the vesicles solubilization.
Analysis of SCLLs vesicle average size by Dynamic Light 
Scattering
Average particle size and size distribution of SCLLs were
measured by photon correlation spectroscopy with a
quasi-elastic laser light scattering (QELS) instrument
(laser source He-Ne, 633 nm and 90° scattering angle).
Vesicle size distribution and the polydispersity indexBMC Dermatology 2001, 1:5 http://www.biomedcentral.com/1471-5945/1/5
(PI) were determined with dynamic light scattering us-
ing a photon correlating spectrometer (SYSTEM 4700-
Malvern). Samples were adjusted to the appropriate con-
centration range with sodium acetate buffer (100 mM,
pH 5.0). Measurements were made at 25°C and scatter-
ing angle of 90°. Cumulative analysis of scattering data
was used to estimate effective diameters and polydisper-
sity.
In vitro permeation and retention studies
Dorsal full-thickness skins of four weeks old male hair-
less mice (strain HRS/J, Jackson Laboratories, Bar Har-
bor, ME), were excised and immediately mounted in a
modified Franz diffusion cell, kept at 37°C. The donor
medium was 0.5 mL, either a SCLLs preparations or
aqueous solution containing the same concentration of
5-ALA. Isotonic pH 5.0 acetate buffer containing forma-
lin 0.01 % (w/w) was used as the acceptor medium, from
which samples were collected at regular intervals during
36 hs. Flux values were obtained from steady state por-
tion of the curve.
For skin retention study in vitro permeation experiments
were performed as described above and the skins were
removed from the diffusion cell after 36 h, cleaned with
cotton soaked in isotonic acetate buffer (100 mM, pH
5.0), and then gently dried by pressing between two tis-
sue papers. SC layers were removed by tape stripping
method, using Scotch Crystal Tape (3M™, France).
About 10 tape-strips were necessary to remove the SC
from the skin samples. 5-ALA present in these tape-
strips was extracted with isotonic acetate buffer. The re-
maining tissue (rest of epidermis + dermis) was homog-
enized in 10 mL of buffer for extraction of 5-ALA and
filtered. 5-ALA amounts presented in the acceptor medi-
um samples and tape strips and epidermis without SC +
dermis extraction solutions were determined by fluori-
metric assay [17]. The pH 5.0 was used in the experi-
ments because the higher 5-ALA stability in this pH.
Results
Figure 1 shows the elution profile of SCLLs obtained by
the phase reverse evaporation technique followed by ex-
trusion, as well as elution of 5-ALA. The extent of drug
entrapped in liposome vesicles can be determined by col-
umn chromatography or by other methods, followed by
drug assay. Liposome preparations are a mixture of en-
capsulated and unencapsulated drug fractions. The un-
encapsulated drug fraction is also referred to as "free"
drug. Free 5-ALA was eluted in the fractions 15–20, dis-
tant from the void volume (Figure 1b). The elution profile
of SCLLs presented by a single peak, close to the col-
umn's void; 5-ALA was also eluted in a unique peak, dis-
tant from the column's void. For the SCLLs samples
prepared with 5-ALA at 1:3 drug:lipids ratio, a degree of
encapsulation around 5.7 (± 0.17) % w/v was found. The
vesicle size distribution determined by photon correla-
tion spectroscopy has showed that SCLLs presented an
average particle size of around 500 nm, in accordance
with the size vesicle obtained by the reverse evaporation
technique [16]. In the presence of 5-ALA, it size was de-
creased to 400 nm (Table 1), indicating possible drug-
vesicle interactions. Figure 2 represents the in vitro per-
meation profile of 5-ALA from SCLLs and aqueous solu-
tion. 5-ALA flux through hairless mouse skin, calculated
after reaching a steady state, was lower for SCLLs formu-
lations (4.2 ± 0.2 µg/cm2.h) than for aqueous solutions
(38.3 ± 2.4 µg/cm2.h). The presence of SCLLS decreased
the amount of 5-ALA transported through hairless
mouse skin, after 36 hours to 500.9 (± 32.5) µg, a value
considerably significantly (P < 0.001) lower than 3681.0
(± 104.65) µg observed for aqueous solutions. However,
the skin retention in the skin layers was increased by
SCLLs formulation significantly (P < 0.05) only in the
epidermis without SC + dermis in comparison with val-
ues for aqueous solution (Figure 3).
Discussion
The obtainment of a liposomal system with a greater in-
teraction with the cutaneous tissue based on the similar-
ity between its lipid composition and that of the SC may
be an adequate strategy for improvement of 5-ALA skin
delivery. Using exclusion chromatography it was possi-
ble to verify the presence of supramolecular aggregates
in the SCLLs preparations obtained in the present study.
SCLLs fractions were eluted with the void volume of the
column and consisted of particles fully excluded from the
internal volume of the gel (7 to 10 fractions; as shown in
the Figure 1(a). Free 5-ALA appeared in the fractions 15
to 20, as illustrated in the Figure 1(b). Size exclusion
chromatography of SCLLs showed a single peak and ves-
icle formation; the individual lipids and smaller vesicles
would elute in fractions distributed over the internal vol-
ume of the gel, distant from the void volume. The lipo-
some fractions collected from the gel filtration column
showed a low degree of about 5.7 (± 0.17) % w/v of 5-ALA
encapsulation. This low percentage of encapsulation
Figure 1
Elution profile of: (a) SCLLs and (b) 5-ALA solutions using
size exclusion chromatography on a Sephadex G-75 column.BMC Dermatology 2001, 1:5 http://www.biomedcentral.com/1471-5945/1/5
may be due to the fact that 5-ALA is a small, hydrophilic
molecule, probably capable of leaking out of the vesicles.
In the presence of 5-ALA, a significant decrease (P <
0.05) of the vesicle size to around 400 nm was observed,
possibly characterizing an interaction at the molecular
level between the drug and the lipids (Table 1).
In vitro permeation and retention studies showed that 5-
ALA in the liposomal system presented a lower permea-
tion through mouse skin (Figure 2). Amazedly, it was ob-
served a significant (P < 0.05) increase in the 5-ALA
retention in epidermis without SC + dermis compared to
aqueous solution (Figure 3). This behaviour can be ex-
plained as a probable consequence of SCLLs-skin inter-
action, providing a deposit effect for 5-ALA in the animal
skin. In fact, liposomes have actually been referred to
skin "drug localizers" [15]. Partition and diffusion in the
SC lipids bilayers are important steps to delivery drugs to
the subsequent skin layers (viable epidermis and dermis)
[18], were most of skin cancer lesions takes place. In the
present work, SCLLS containing 5-ALA showed ade-
quate retention of the drug in the epidermis without SC
+ dermis, with decreased transdermal delivery (Figure
3). This behaviour shows that the liposomal system
based on lipid composition similar to SC lipids provided
a target delivery of 5-ALA into skin tissue to be treated in
the topical PDT of skin cancer. Despite the low degree of
5-ALA encapsulation in SCLLs, a suitable 5-ALA delivery
into skin, as well as its slower rate of permeation were
observed. These properties are interesting to ensure
PpIX formation over an adequate time period and
amount. Our previous work [19] showed that lecithin in
poloxamer gels can increase skin retention of hidrocorti-
sone acetate into hairless mouse skin; they attributed
this results to the increased lipid content of the SC
caused by the phospholipid, in special within the SC
intercellular region. Similarly to SC, SCLLs have cera-
mides (50%) as the major lipid. This property may in-
crease formulation-SC interactions faciliting thus, the
partition of 5-ALA into the skin. The higher amount of 5-
ALA in the epidermis without SC + dermis can be ex-
plained because 5-ALA is polar and charged. It can be
partitioned promptly to the aqueous skin layers, despite
SCLLs formulation is retained in the SC. For lipophilic
drugs, it could find a higher retention in the SC, since
SCLLs provide a favorable environment for these drugs.
Other authors [20] have found by an in vivo stripping
technique, that SCLLs showed a high affinity for SC indi-
cated by a high amount of a fluorescent marker (sodium
fluorescein), and suggesting a greater reservoir capacity
of SC compared to similar lipid composition formulation
(not a liposomal system). Liposome formulation based
on phospholipids can interact with SC destabilizing, and
fusing or mixing with the lipid matrix, acting as permea-
tion enhancers and increasing the transdermal delivery
[21]. SCLLs effect found in the present work is desirable
for topical drug delivery [22], in special for skin cancer
treatment based on 5-ALA PDT, in which a high 5-ALA
skin retention may lead to greater PpIX accumulation
into the skin. Since the success of this therapy is related
to the amount of PpIX formed in the target tissue (viable
epidermis and dermis), more efficient therapeutic effect
may be expected from its utilization.
Conclusions
Liposomal preparations obtained using commercial lip-
ids; the so-called SCLLs appear to be a useful 5-ALA de-
Figure 2
Amount of 5-ALA permeated (µg/cm2) through hairless
mouse skin from the 5-ALA aqueous solution (black star) and
SCLLs (square), as a function of time (hours).
Table 1: Values of SCLLs sizes and their polidispersity using pho-
ton correlation spectroscopy*
Preparation Mean size (nm) P.I.**
SCLLs alone 500.0 0.570
SCLLs containig 5-ALA 400.1 0.570
(drug:lipids, 1:3)
* Scattering angle of the laser beam was 90°; temperature 25°C, viscos-
ity 0.890 and refraction index 1.33. **Polidispersity index, meaning the 
measurement of the homogeneity of a dispersion, ranging from 0.0 
(monodisperse) to 1.0 (very heterogeneous).BMC Dermatology 2001, 1:5 http://www.biomedcentral.com/1471-5945/1/5
livery system for topical PDT in skin cancers.
Considering that adequate skin bioavailability of 5-ALA
is important for this therapy, SCLLs preparations pro-
vided a good performance, by a slower permeation and
delivery of the drug into epidermis without SC +dermis
compared to aqueous solutions usually applied in 5-
ALA-PDT clinical procedure. A lipid bilayer structure,
similar to SC lipid matrix is another advantage of SCLLs
in favor of their interaction with the skin. Other authors
[23] have found that these preparations permit a higher
turnover of the skin barrier in comparison to a simple li-
pid mixture. Delivery systems that increase 5-ALA con-
centration in the target skin layers may improve the
efficacy of topical PDT with this drug, since the PpIX ac-
cumulation is directly related to the presence of 5-ALA in
the skin [1]. The encapsulation problem found in the
present work may in part be solved by the use of ester de-
rivatives of 5-ALA [11], which present higher molecular
weight and lipophilic characteristics than 5-ALA itself,
which can provide higher encapsulation degree and infer
in improved retention into the target tissue with conse-
quently improvement of PpIX accumulation.
The results obtained in this work, indicate that SCLLs
formulations appear to be suitable for topical delivery of
5-ALA. Efficiency of encapsulation, stability of SCLLs
containing 5-ALA or its ester derivatives, skin permea-
tion profiles as well as in vivo PpIX production in treated
skin, remain to be optimized in order to fill the gap in
knowledge about drug delivery systems to be used in
PDT.
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